Ipsos Healthcare Launches Syndicated MS Patient Community Panel
Ipsos Healthcare has announced the launch of its syndicated Multiple Sclerosis (MS) Patient Community Panel, part of the Ipsos Healthcare Global Patient Centre of Excellence. The MS Patient Community Panel comprises MS patients across the EU5 and US with a mix of treatment experiences. They will take part in a range of tasks throughout the year (both syndicated and proprietary), moderated by Ipsos Healthcare’s MS experts. This format will enable subscribers to explore key topics throughout the year, whilst also tapping into the community to answer business questions as they arise. Paul O’Meara, Head of Real World Evidence in Autoimmune Diseases at Ipsos Healthcare, commented: “As patients move from recipients to participants, there is an imperative for pharma to put patients at the heart of current and future business models. Designed with this objective in mind, the MS Community will enable our clients to identify unmet patient needs, optimise their patient communications, assess new ideas, and develop personalized medicine strategies for those living with MS.”
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
